Field consensus 2018-2022 shifted from soluble-Aβ targeting (solanezumab class) to aggregated-Aβ + protofibril targeting (lecanemab, donanemab, aducanumab); EXPEDITION3 read as definitive evidence that soluble Aβ is downstream marker not therapeutic substrate.

Evidence span

Field consensus 2018-2022 shifted from soluble-Aβ targeting (solanezumab class) to aggregated-Aβ + protofibril targeting (lecanemab, donanemab, aducanumab); EXPEDITION3 read as definitive evidence that soluble Aβ is downstream marker not therapeutic substrate.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

Field-level scope refinement post-EXPEDITION3, anchored in 2019-2022 review literature.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required